Moomoo AI 已提取核心訊息
On February 2, 2024, Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, reported a significant stake in Invivyd, Inc. According to the Schedule 13G filed with the SEC, the group collectively owns 9,000,000 shares of Invivyd's common stock, which represents 7.56% of the company's class of securities. The filing, made under Rule 13d-1(c), indicates that the shares are held with shared voting and dispositive power. The principal business offices for Deep Track Capital and David Kroin are located in Greenwich, CT, while Deep Track Biotechnology Master Fund is based in the Cayman Islands. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Invivyd, Inc., and there...Show More
On February 2, 2024, Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, reported a significant stake in Invivyd, Inc. According to the Schedule 13G filed with the SEC, the group collectively owns 9,000,000 shares of Invivyd's common stock, which represents 7.56% of the company's class of securities. The filing, made under Rule 13d-1(c), indicates that the shares are held with shared voting and dispositive power. The principal business offices for Deep Track Capital and David Kroin are located in Greenwich, CT, while Deep Track Biotechnology Master Fund is based in the Cayman Islands. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Invivyd, Inc., and there is no intention to participate in any transaction with such a purpose or effect. The statement was duly signed by David Kroin, who serves as the Managing Member of the General Partner of the Investment Adviser for Deep Track Capital, LP, and as a Director for Deep Track Biotechnology Master Fund, Ltd.
2024年2月2日，Deep Track Capital, LP以及Deep Track Biotechnology Master Fund, Ltd.和David Kroin報告了Invivyd, Inc.的大量股份。根據向美國證券交易委員會提交的附表13G，該集團共擁有900萬股普通股，佔該公司證券類別的7.56％。根據第13d-1（c）條提交的文件表明，股份持有的是共同的投票權和處置權。Deep Track Capital和David Kroin的主要業務辦公室位於康涅狄格州格林威治，而Deep Track Biotechnology主基金則設在開曼群島。該文件稱，收購這些股份不是爲了改...展開全部
2024年2月2日，Deep Track Capital, LP以及Deep Track Biotechnology Master Fund, Ltd.和David Kroin報告了Invivyd, Inc.的大量股份。根據向美國證券交易委員會提交的附表13G，該集團共擁有900萬股普通股，佔該公司證券類別的7.56％。根據第13d-1（c）條提交的文件表明，股份持有的是共同的投票權和處置權。Deep Track Capital和David Kroin的主要業務辦公室位於康涅狄格州格林威治，而Deep Track Biotechnology主基金則設在開曼群島。該文件稱，收購這些股份不是爲了改變或影響Invivyd, Inc. 的控制權，也無意參與任何具有此類目的或效果的交易。該聲明由戴維·克羅因正式簽署，他是Deep Track Capital, LP投資顧問普通合夥人的管理成員和Deep Track Biotechnology Master Fund, Ltd的董事。
有用
沒用